Invitrogen Files for Triple Damages in Ongoing Cell Products Patent Suit Against Stratagene | GenomeWeb
Invitrogen is continuing to seek enhanced damages in a patent infringement case against Stratagene, arguing in court documents earlier this month “that Stratagene earned huge profits from its many years of infringement, and did so willfully.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.